CU6
data caveat$782M27mo
Clarity Pharmaceuticals
Biotech · Radiopharmaceuticals
Copper-based radiopharmaceuticals for cancer imaging and therapy, SAR-bisPSMA lead program
Data HealthTrials4 of 4 active · stale enrollment
Cash data from Dec 2025 4C(5mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$226.3M
Dec 2025 4C
Runway
27moSTABLE
Based on Dec 2025 4C
Market Cap
$782M
Burn Rate
$25.1M/qtr
Dec 2025 4C
Shares Outstanding
372M
Pipeline Assets
3
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther13 May 2026
Clarity receives $9.8 million R&D tax incentive refund
Clarity Pharmaceuticals received a $9.8 million R&D tax incentive refund from the Australian Federal Government for eligible R&D activities in FY2025. The non-dilutive funding will extend cash runway and support development of the company's Targeted Copper Theranostic platform, including SAR-bisPSMA and SARTATE products in late-stage trials.
3M Price
CU6.ASX$2.110-44.3% 3M
Low $2.110High $3.830
Pipeline Assets (3)
Capital Raises & Buybacks
12mo dilution 0.1%2 raises
Current shares outstanding: 372M
Options
2026-03-31options exercise
0
2026-03-11options exercise
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
1 transactionLast 90dNet Sell
Buys0
Sells1+1 vs prior
Sell Value$1103k
Catalysts (10)· 4 upcoming · 6 past
SARTATE Phase 3 NETs trial start
UpcomingConfirmedremoveMed30 June 2026
CLARIFY trial enrolment close
UpcomingExpectedarrow_upwardHigh30 June 2026
AMPLIFY Phase 3 topline data
UpcomingExpectedarrow_upwardHigh30 Sept 2026
SECuRE Phase I/IIa continued enrolment
UpcomingExpected
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High89/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 10 tracked
What drove these scores · rolling 2yr
arrow_drop_down
1 burn spike — Quarter-on-quarter spend increase >50%
arrow_drop_up
Burn reductions achieved — 1 quarter with >30% spend reduction
arrow_drop_up
Cash position improving — Cash balance grew over last 3 quarters
arrow_drop_up
R&D-focused spend — 91% of opex directed to R&D
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Completed catalysts
✓Clarity receives $9.8 million R&D tax incentive refund— Clarity Pharmaceuticals received a $9.8 million R&D tax incentive refund from the Australian Federal Government for eligible R&D activities in FY2025. The non-dilutive funding will extend cash runway and support development of the company's Targeted Copper Theranostic platform, including SAR-bisPSMA and SARTATE products in late-stage trials.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(11)
4 activeClinicalTrials.gov ↗
Ph1/PHASE2RecruitingEnrollment stale · 1764d
64Cu-SAR-bisPSMA67Cu-SAR-bisPSMA
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Prostatic Neoplasms, Castration-Resistant
18 Years+
Primary endpoint Biodistribution of 64Cu-SAR-bisPSMA
ENROL54
no manual snapshots — enter via record_enrollment.py
Ph2RecruitingEnrollment stale · 566d
64Cu-SAR-bisPSMA
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
Prostate Cancer (Post Prostatectomy)
18 Years+
Primary endpoint Detection rate of lesions per participants, between 64Cu-SAR-bisPSMA and 68Ga PSMA-11 PET/CT
ENROL50
no manual snapshots — enter via record_enrollment.py
Ph3RecruitingEnrollment stale · 902d
64Cu-SAR-bisPSMA
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Prostate Cancer · Prostatic Neoplasms
18 Years+
Primary endpoint Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases
ENROL383
no manual snapshots — enter via record_enrollment.py
Announcements(20)
article
OtherPSauto_awesome
Clarity receives $9.8 million R&D tax incentive refund13 May 2026
expand_more168KB